Indira Menon, MD
Ophthalmology · Decatur, GANPI 1164423075
Payments from drug & device makers
Across 238 payments — averaging $38.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$2K
- Sun Pharmaceutical Industries Inc.$1K
- AbbVie$987
- Glaukos Corporation$745
- Johnson & Johnson Surgical Vision, Inc.$521
- Alcon$436
- plus $3K from 29 others
What the payments were for
- Travel & lodging$1,78320%
- Food & beverage$7,19880%
- Entertainment$671%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 11 | $2,021 |
| Sun Pharmaceutical Industries Inc. | 38 | $1,182 |
| AbbVie(2 entities) | 45 | $987 |
| Glaukos Corporation | 13 | $745 |
| Johnson & Johnson Surgical Vision, Inc. | 18 | $521 |
| Alcon | 17 | $436 |
| Oyster Point Pharma, Inc. | 9 | $357 |
| Amgen(2 entities) | 14 | $346 |
| Bausch & Lomb Americas Inc. | 8 | $253 |
| Kala Pharmaceuticals, Inc. | 8 | $251 |
| Aerie Pharmaceuticals, Inc. | 3 | $245 |
| Akorn Operating Company LLC | 3 | $213 |
| Novartis | 11 | $199 |
| Harrow Eye, LLC | 4 | $186 |
| Mallinckrodt Hospital Products Inc. | 4 | $174 |
| Rxsight Inc | 4 | $136 |
| Mallinckrodt Enterprises LLC | 1 | $120 |
| Akorn, Inc. | 3 | $91 |
| Thea Pharma Inc. | 4 | $89 |
| Optos, Inc. | 1 | $67 |
| Tarsus Pharmaceuticals, Inc. | 2 | $51 |
| AstraZeneca | 1 | $50 |
| Sight Sciences, Inc. | 3 | $50 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $34 |
| ANI Pharmaceuticals, Inc. | 1 | $32 |
| Springworks Therapeutics, Inc. | 1 | $29 |
| GSK | 1 | $26 |
| Eyepoint US, Inc. | 1 | $24 |
| Coopervision Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $23 |
| Dompe US, Inc. | 1 | $22 |
| Carl Zeiss Meditec USA, Inc. | 1 | $18 |
| Ocular Therapeutix, Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $15 |
| Omeros Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rhopressa$351
- Rocklatan$351
- TYRVAYA$250
- BROMSITE$233
- KXL System$226
- CEQUA$212
- Zioptan$167
- Prokera$144
- AmnioGraft$144
- CE-marked KXLA system$128
- VEVYE$123
- ACTHAR$120
- Photrexa$118
- INVELTYS$115
- Catalys Laser System$111
- MIEBO$110
How this compares
$9,048 in reported general payments places this provider in the 80th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 213 | $128,875 |
| RestasisCyclosporine | 51 | $75,033 |
| XiidraLifitegrast | 17 | $27,290 |
| Cyclosporine | 30 | $24,563 |
| MieboPerfluorohexyloctane/Pf | 12 | $18,899 |
| VyzultaLatanoprostene Bunod | 20 | $17,578 |
| TyrvayaVarenicline Tartrate | 14 | $8,351 |
| Travoprost | 31 | $8,265 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $6,255 |
| RhopressaNetarsudil Mesylate | 11 | $5,745 |
| Brimonidine Tartrate | 30 | $5,555 |
| Alphagan PBrimonidine Tartrate | 11 | $5,276 |
| ZirganGanciclovir | 11 | $4,816 |
| Loteprednol Etabonate | 19 | $3,741 |
| Latanoprost | 269 | $3,019 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $987 | $215,439286 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta, Zirgan | $253 | $68,58360 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $357 | $8,35114 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $245 | $5,74511 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $34 | $3,74119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 481 ophthalmology providers in Georgia.
Other ophthalmology in Decatur
- Dennis MarcusAugusta$9.2M
- Robert StoltzMarietta$3.9M
- Eugene McLaurinSavannah$3.3M
- Clayton BlehmGainesville$1.7M
- Lakshmana KooragayalaMarietta$1.4M
- Douglas DayAtlanta$1.1M
- Jennifer KimMorrow$989K
- Thomas AabergAtlanta$959K
- Gagan SawhneyAtlanta$874K
- Lawrence WoodardAtlanta$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.